A Study About the Development of Learning in African-American/Black Children
The purpose of this study is to investigate the early development of attention, learning, and memory during childhood. Participation in this study includes 4, 90-minute-long visits to the lab per year. During these visits, your child will play 2-3 fun, computerized games. These games are designed to assess various aspects of their cognitive ability.
The duration of the study will last 4 years.
Eligibility Criteria:
- African-American/Black children who are 4 years old
A Study About Gene Therapy for Early Alzheimer’s Disease (AD) and Mild Cognitive Impairment (MCI)
The primary aim of this study is to determine whether administration of the nervous system growth factor "Brain-Deruved Neurotrophic Factor" (BDNF) to eligible patients with Alzheimer's disease and Mild Cognitive Impairment is safe and tolerable. This study will be used to determine whether BDNF administration reduces neuronal loss and rebuilds synapses in the brain of patients with Alzheimer's Disease (AD) and Mild Cognitive Impairment (MCI).
- Male and Females aged 50 years or older
- Diagnosis of dementia due to Alzheimer's Disease/Diagnosis of Mild Cognitive Impairment (MCI) due to Alzheimer’s Disease
- A caregiver is available who has frequent contact with the subject, agrees to observe for adverse events, and will accompany the subject to all clinic visits for the duration of the protocol
- CT or MRI scans within 24 months prior to screening without evidence of an infection, infarction, or other focal
Inclusion Criteria varies, please contact Study Coordinator for more information.
The below Exclusion Criteria apply to both the AD and MCI groups.
- Any significant neurological disease other than suspected incipient disease
- History of schizophrenia
- History of systemic cancer within the past 18 months (non-metastatic skin cancers are acceptable).
- Any significant systemic illness or unstable medical conditions which could lead to difficulty complying with the protocol
- Use of any investigational drugs within thirty days or five half-lives, whichever is longer, prior to screening.
Exclusion Criteria varies, please contact Study Coordinator for more information.
Sleep and Blood Sugar in People with Alzheimer's Disease
The purpose of this study is to learn about sleep and blood sugar (glucose) levels in people living with Alzheimer’s disease (AD). Another purpose of the study is to see how people with AD and their caregivers/family members feel about wearing small devices to measure sleep and blood sugar.
The duration of this study is 10 days.
- 60 years or older, with Alzheimer’s disease,
- Has a caregiver 18 years or older,
- Willing to wear a watch-like device,
- Willing to wear a small sensor on the skin
An Observational Study to Examine School Transition after Traumatic Brain Injury
The purpose of this study is to understand the best ways to help students return to school after brain injury of any severity. This is important to study because finding the best ways to help students go back to school right after brain injury, and over time, can help improve student success and recovery.
Your participation in the study would take place when you/your child begins the study and then at 3 months, 6 months, 12 months, 2 years (if applicable) and 3 years (if applicable) after the study starts.
• Students aged 5 to 18 years old
• In kindergarten through 12th grade
• Must Speak English
• Traumatic Brain Injury (TBI) of any severity
• Parent/caregiver is willing to share medical and academic information with the research team (all study activities are virtual/remote)
Perinatal Arterial Stroke: The I-ACQUIRE Study
Children who suffered a stroke before or shortly after being born that was caused by blockage of blood flow in an artery, it often results in the child showing some weakness on one side of their body.
With this study, we want to find out if a type of therapy may help children who have weakness on one side of their body due to perinatal arterial ischemic stroke, learn how to better use their weaker arm.
All children will be in the study for about 13 - 15 months. Some children may be in the study for a longer period, depending on which treatment they receive during Phase 1 of the study. The I-ACQUIRE therapy involves fun learning and play, self-help activities, and manipulating interesting toys and objects.
- Your child must be between the ages of 8 and 36 months old when beginning this study
- Your child must have suffered an a perinatal arterial ischemic stroke
- Upper limb weakness
- Parents must be able to participate at least 1x/week for therapy and 40-60 minutes/day at home
A study on language impairment following a stroke
This NIH-funded project will investigate patient-specific factors that may influence response to therapy for language impairment after stroke, or aphasia. Results from this work will assist with better estimation of prognosis for stroke survivors with aphasia, which could empower patients and families to make more informed health care decisions about how to pursue the most appropriate rehabilitation services based on their unique characteristics, such as genetics, cognitive skills, and brain structure after stroke.
Participants must meet the following criteria:
- Native English speaker
- Able to have an MRI
- Had only one stroke (in the left hemisphere of the brain)
Cognition and Brain Circuitry
The purpose of the study is to look at how our brain networks interact for different mental functions and how individual differences in brain structure and function determines individual differences in behavior. During this study, we use magnetic resonance imaging methods: functional magnetic resonance imaging (fMRI) and diffusion weighted imaging (DWI). Functional MRI (fMRI) and DWI are typical imaging methods that use a strong magnetic field and radio waves to make pictures of your body. The total length of the study will be between 3 and 4 hours, including up to 2 hours outside the MRI scanner and 2 hours in the scanner.
- Healthy adults between 18-40 years of age - Have normal or corrected-to-normal vision
Vercise™ DBS Registry
The purpose of this study is to record the personal experiences of those who have had Deep Brain Stimulation (DBS) using the Vercise™ System, for the treatment of Parkinson's Disease.
You may be eligible if you are:
- At least 18 years of age
- Planning to receive the currently available Vercise™ System and/or any new commercially approved parts such as leads, extension, Adaptor, CP, etc. that is works with the Vercise System
Abbott DBS (Deep Brain Stimulation) Registry
The purpose of this study is to collect information and evaluate outcomes for Abbott Deep Brain Stimulation (DBS) systems that are approved and sold in your country.
In order to evaluate how the DBS system performs, data will be collected before, during and after DBS implant when you visit the study doctor. The data collected will include information on your movements, feelings, daily activities, and DBS program settings.
The information gathered in this study will add to the understanding of treatment options for future patients receiving DBS.
Inclusion Criteria:
- You are scheduled for a new implant or IPG device replacement surgery with a market-released Abbott DBS system within 3 months
Exclusion Criteria:
- You are currently enrolled or plan to enroll in another study that may alter the results of this clinical investigation
- You have another disease, conditions, or other medical, social, or psychological conditions that could limit the your ability to participate in the clinical investigation or to satisfy follow-up requirements
A Study to Evaluate an Investigational Drug (NLY01)Treatment to be used in Early-Stage Parkinson’s Disease
This research is studying a new drug, NLY01, in a large number of persons to learn about its effects in people with early-stage Parkinson’s disease (PD). Researchers want to know whether NLY01 helps lessen symptoms and signs of early PD, as well as slow the progression of the disease.
You will have a 2 in 3 chance of receiving NLY01 and a 1 in 3 chance of receiving a placebo, sterile salt water that looks like NLY01 but does not contain the study drug.
The total amount of time for you to be in the study will be approximately 45 to 54 weeks.
Inclusion:
- Man or woman, at least 30 to 80 years old
- Have early-stage Parkinson's disease
- Not be on any current treatments for PD
- If of reproductive potential, willing and able to use a highly effective form of birth control during the study and for 30 days following last dose of study material
* Other criteria for eligibility apply
Exclusion:
- Diagnosis of secondary or atypical parkinsonism
- Onset of any parkinsonian motor sign or symptom >5 years before Screening Visit
- Previous surgical procedure for PD
- Clinically significant medical, surgical, psychiatric, or laboratory abnormality
- Has an ECG or clinical evidence of potentially unstable heart disease
- Medical or recreational use of marijuana or THC-containing compounds within 3 months of the Screening Visit
* Other criteria for exclusion apply